Video

Dr Michael Thase Discusses Treating Major Depressive Disorder

In the last 30 years, there have been easier to prescribe, safer antidepressants for major depressive disorder, as well as the introduction of easy-to-learn approaches to therapy, but 40% or so of people suffering from depression aren’t in treatment, explained Michael Thase, MD, professor of psychiatry and director of the Mood and Anxiety Program at the University of Pennsylvania.

Michael Thase, MD, professor of psychiatry and director of the Mood and Anxiety Program at the University of Pennsylvania, explains how major depressive disorder is typically treated, as well as the greatest challenges in treating the disorder.

TranscriptHow is major depressive disorder typically treated?

The largest public health advance in the care of depression in the last 30 years was the introduction of easier to prescribe, safer antidepressants that made it possible for many depressed patients to be treated in primary care. At the same time, relatively easy-to-learn approaches to therapy involving core interpersonal issues or cognitive behavioral strategies also became increasingly available.

Now, these treatments aren’t as widely and broadly available as pharmacotherapy, and, sometimes, they’re used in combination with pharmacotherapy. But, between the newer generation antidepressants and the focused psychotherapies, probably 6 or 7 out of 10 depressed people seeking care in the outpatient side of the world can get better within 3 or 4 months.

What are the greatest challenges in treating this disorder?

So, the number one challenge is that, at any moment in time, 40% or so of people suffering from depression aren’t in treatment whatsoever. So, ways of making the benefits of treatment more broadly known and more accessible to people is one challenge. Another challenge, of course, is for the people who seek treatment but for whom our standard treatments aren’t effective. And there’s a subset, maybe as large as 20% or 25% for whom our standards medications and standard therapies don’t work.

Related Videos
Bridgette J. Picou, LVN, ACLPN, The Well Project
Mia Moore, PhD, Fred Hutch Cancer Center
Steven Daniel Daveluy, MD, FAAD
Shawn Kwatra, MD, FAAD
Elizabeth Jones, MD, FAAD.
Brittany Craiglow, MD, FAAD
Lawrence F Eichenfield, MD, FAAD.
Douglas Flora, MD, FACCC
Rebecca Vasquez, MD, FAAD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo